Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06662162

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.

Participants will:

* Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months. * Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.

Recruiting

Interested in participating?

Request Info

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sydney Eye Hospital, Sydney, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Presence of at least one large druse >125 microns in diameter due to AMD.
  • BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6/12 to 6/60 [20/40 to 20/200])

Key Exclusion Criteria:

  • Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and/or cardiac defibrillator/pacemaker.
  • Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and/or the grounding electrode (base of the hairline on the back of the neck).
  • Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) >10% (13.3 mmol/L).
  • Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).
  • Known severe allergy to fluorescein dye.
  • Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).
  • History of seizure disorders, chronic migraines and/or cluster headaches.
  • History and/or evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.
  • Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).
  • History and/or evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.
  • GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.
  • History of intravitreal injections for GA (e.g., Syfovre or Izervay).
  • Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.
  • Glaucoma requiring ≥3 medications and/or drops per day, or history of trabeculectomy.
  • History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.
  • History of yttrium aluminium garnet (YAG) laser posterior capsulotomy <1 month from Screening.
  • Visually significant cataracts and/or visually significant posterior capsular opacification.
  • History of amblyopia.

Treatment and study plan

i-Lumen AMD

Device

i-Lumen AMD transpalpebral microcurrent stimulation system

Primary outcomes

  1. Mean Change BCVA from Baseline

    Time frame: Month 3

    Mean change in per-eye (treated study eye [unilateral] or treated primary study eye [bilateral]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.

Secondary outcomes

  1. Portion of per-eye Responders

    Time frame: Month 3

    • Difference in proportion of per-eye (treated study eye [unilateral] or treated primary study eye [bilateral]) gaining ≥10 letters from Baseline in distance BCVA ETDRS, active vs sham.
  2. Mean Change BCVA from Baseline

    Time frame: Month 6

    Mean change in per-eye (treated study eye [unilateral] or treated primary study eye [bilateral]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.

Study contacts

Contact information is provided by the study sponsor or research team.

Meredith Mundy

CONTACT

[email protected]

408-440-7049

Sponsors and collaborators

Lead sponsor

i-Lumen Scientific AUS PTY LTD

Industry

Collaborators

  • i-Lumen Scientific, Inc.

Registry information

Official study title

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.

Acronym: i-SIGHT2

Important dates

Study start
2025
Primary completion
2027
Study completion
2029
First posted
Oct 28, 2024
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.